This study of 12 patients with mild-to-moderate hypertriglyceridemia compares the mechanisms of triglyceride (TG) lowering by caloric restriction and by clofibrate. Turnover rates of very low density lipoprotein triglycerides (VLDL-TG) were determined by using 3 H-glycerol as a precursor. Radioactivity-time curves of VLDL-TG were analyzed with a multicompartmental model. Hypertriglyceridemia in these patients was due mainly to overproduction of VLDL-TG. Clofibrate therapy for 1 month had a variable effect on VLDL-TG levels. A group of relatively poor responders to the drug had a mild increase in the fractional catabolic rate (FCR) of VLDL-TG, but no change in production rates. The remaining patients were relatively good responders; they had increased FCR and modest reductions in synthetic rates of VLDL-TG. However, clofibrate largely failed to correct the primary defect in this group of patients, namely, the overproduction of VLDL-TG. Almost all patients responded to 1 month of caloric restriction (1000 cal/day) with marked reductions in VLDL-TG levels. The major response to reduced caloric intake was a decrease in production of VLDL-TG, although FCR was also increased to some extent. Despite these differences in mechanisms for VLDL-TG lowering, both regimens tended to raise levels of LDL and HDL.
A lthough hypertriglyceridemia is an important clinical problem, investigations into its causes, as well as into mechanisms by which it can be modified, have been hampered by an inadequate methodology for studying triglyceride metabolism. Early methods had distinct limitations. However, the recent introduction of multicompartmental analysis to assess kinetics of very low density lipoprotein-triglyceride (VLDL-TG) appears to have overcome some of these limitations. 1 The present study used multicompartmental analysis in an attempt to distin-guish the mechanisms by which caloric restriction and a drug, clofibrate, lower plasma TG. Several actions have been reported for both. Caloric restriction is thought to mainly decrease the input of VLDL-TG; 2 clofibrate reportedly lowers the production of VLDL-TG 3 -7 but also enhances its clearance. 4 ' 8 " 10 To further compare these two regimens, the following questions were addressed: 1) What are the relative potencies of caloric restriction and clofibrate in lowering plasma TG levels? 2) Do these two regimens reduce TG concentrations by the same or different mechanisms? 3) How do they compare in their effects on concentrations of low density lipoproteins (LDL) and high density iipoproteins (HDL)? 4) Do they lower plasma TG in a beneficial way for the treatment of patients with mild-to-moderate hypertriglyceridemia?
Methods

Patients
Twelve patients were admitted into the Special Diagnostic and Treatment Unit (metabolic unit) of the Veterans Administration Medical Center, San Diego, California. The sex, age, percentage of ideal body weight, 11 body weight at the end of each period, and diagnosis of each patient are presented in Table 1 . All patients had hypertriglyceridemia upon admission. Several patients had mild abnormalities in glucose tolerance characteristic of patients with hypertriglyceridemia; 12 none, however, had fasting hyperglycemia or required hypoglycemic agents. Family screening for genetic forms of hyperlipidemia 13 ' 14 was not carried out. One patient (No. 11) had mild fasting chylomicronemia during the control period. Three others (Nos. 6, 8, 12) had LDL cholesterol levels very near the 95th percentile of the Lipid Research Clinics Prevalence Study. 15 The remainder of the patients had increases only in VLDL. Most patients had clinical atherosclerotic disease; the exceptions were two women (Nos. 6 and 11), one relatively young man (No. 5), and one elderly man with mild hypertriglyceridemia (No. 9). None had unstable angina, congestive heart failure, or evidence of liver or gastrointestinal disease. One had previous cholecystectomy. All patients gave informed consent for the investigation.
Experimental Design
Patients were studied during three periods; each period lasted approximately 1 month. The first period was for control (except for Patients 3 and 12, whose first period was clofibrate treatment). In the second period, clofibrate was given in doses of 2 g/day (1 g twice daily). All patients tolerated the drug well and had no significant side effects. Caloric restriction was carried out during the third period. One patient (No. 1) had only 2 weeks of caloric restriction because he was mildly underweight at the beginning of the study and could not tolerate a prolonged reduction in caloric intake. At the end of each period, the patients were studied for kinetics of plasma VLDL-TG.
Six patients (Nos. 2, 3, 4, 6, 8, and 9) underwent dietary and drug regimens as outpatients; they were admitted to the hospital 2 days before their study of VLDL-TG kinetics. These patients were on an ad libitum diet at home during the control and clofibrate periods; all patients except one (No. 8) maintained a constant weight throughout the first two periods; Patient 8 showed a sizable weight loss even though he reported no change in caloric intake during the two periods. During the third period, the patients consumed a diet containing the usual distribution of fat, carbohydrates and protein, but only 1000 kcal/day. These patients were counseled by a dietitian, monitored frequently, and in the third period showed constant weight loss. The remaining six patients were hospitalized throughout the study; they were fed a diet of mixed solid food and liquid formula containing 40% of the calories as fat, mostly in the form of lard. The basic composition and pattern of this diet have been previously described in detail. 16 Cholesterol intakes ranged between 100 and 200 mg/day. Vitamin and mineral supplements were given daily. Each patient was weighed daily, and caloric intake was adjusted to maintain total body weight at a constant level throughout the control and clofibrate periods. One patient (No. 5) nonetheless showed some drop in weight on clofibrate even though his caloric intake remained unchanged in the two periods. The 1000 kcal diet of these patients had the same composition of protein, fat, and carbohydrates as in the weight maintenance diet.
Triglyceride Kinetics
Kinetics of VLDL-TG were studied by methods previously from our laboratory. 1 For this test, 3 H-glycerol was used as a precursor for labeling VLDL-TG. Each patient was given a fat-free, liquid diet every 3 hours around the clock for 36 hours before the injection of 3 H-glycerol and for 48 hours after the injection. In the weight-maintenance and clofibrate periods, this diet contained 60% of the calories needed to maintain weight in the pretest level. During the clofi- brate period, the patients were given their usual dosage of the drug every 12 hours throughout the turnover study. During caloric restriction, 600 kcal (60% of 1000 kcal) per 24 hours was given. Removal of fat from the diet was necessary to prevent contamination of VLDL-TG with intestinal chylomicron-TG. Maintenance of some caloric intake was needed to prevent a fall in VLDL-TG that would result from prolonged fasting. 17 The fat calories removed from the diet were not replaced by carbohydrate to prevent carbohydrate-induced elevation of plasma TG. 12 Even so, a mild rise in VLDL-TG levels sometimes occurred in the 36-hour equilibration period before the injection of 3 H-glycerol; this rise, which can be relatively slow and has been noted previously, 1 explains the need for the 36-hour period of equilibration. For the subsequent 48 hours, VLDL-TG concentrations were relatively constant, showing neither a rise nor fall; this constancy held during the caloric restriction period.
After the 36-hour equilibration period, 300 /xC\ of 2-3 H-glycerol (New England Nuclear Corporation, Boston, Massachusetts) were given intravenously, and blood samples were drawn at 15 minutes, 30 minutes, and 1.0, 1.5, 2.0, 2.5, 3, 4, 5, 6, 9, 12, 15, 18, 24, 30, 39, 48 hours. Blood samples containing EDTA were immediately centrifuged at 3000 rpm for 20 minutes at 5° C. The plasma was stored at 4° C. VLDL was isolated by preparative ultracentrifugation, 18 and the specific activities of VLDL-TG were estimated along with the cholesterol content as recently described. 1 -ia M Patient 11, who had mild fasting chylomicronemia during the control period, had no visible chylomicrons during the test when the diet was free of fat.
All kinetic data were fitted to the multicompartmental model of the endogenously labelled VLDL-TG developed by Zech et al. 1 This model was developed to account for the different components of the specificactivity curve of VLDL-TG. Analysis of VLDL-TG kinetics were performed on a Digital VAX/VMS computer using the SAAM program (version 27) of Berman and Weiss. 21 The fractional catabolic rate (FCR) of VLDL-TG, the transport rates (production rates) of VLDL-TG, and the distribution between the slow and fast pathways of VLDL-TG synthesis were calculated from the estimated parameters.
Plasma Llpids and Lipoproteins
Blood for quantification of plasma total cholesterol and total TG and lipoprotein-cholesterol was obtained after a 12-hour fast. Samples were obtained several times in the last 2 weeks of each period, more in the inpatients than outpatients, to monitor the response to each regimen. Total cholesterol and TG were determined on a Technicon Auto-Analyzer (Model II, Technicon Instruments Corporation, Tarrytown, New York).' 920 Concentrations of cholesterol in LDL and HDL were estimated as described in the Lipid Research Clinics Manual of Laboratory Operations. 22 
Results
Plasma Llpids and Lipoproteins
Mean values for plasma total lipids and for cholesterol in LDL and HDL during the three periods are given in Table 2 . In the control period (Period 1), plasma TG levels ranged from 300 to 910 mg/dl (mean = 488 ± 60 SEM mg/dl). Mean levels of LDL cholesterol and HDL cholesterol were 147 ± 12 mg/dl and 31 ± 2 mg/dl, respectively. Treatment with clofibrate produced a reduction in plasma TG averaging 34%. During clofibrate therapy, LDL cholesterol rose by 27%, but HDL cholesterol was not significantly increased. With caloric restriction, plasma TG fell by 41 %; LDL cholesterol increased significantly, but only by 15%; and HDL cholesterol also rose significantly (23%).
The response in TG lowering was relatively consistent with caloric restriction, but it was more heterogenous during clofibrate therapy. Some patients were good responders to clofibrate, but others were rather poor; thus, we carried out a subgroup analysis based on the degree of lowering of VLDL-TG. Those whose VLDL-TG levels fell 20% or less were called poor responders (Table 3) , while those who had a greater reduction were labeled good responders (Table 4 ). Poor responders to clofibrate had insignificant changes in total cholesterol, TG, and HDL cholesterol; even so, they had a striking increase in LDL cholesterol (33%). These patients in contrast responded to caloric restriction by a significant fall in TG levels, a lesser rise in LDL cholesterol, and a significant increase in HDL cholesterol. For the good responders, clofibrate therapy produced a reduction in total TG averaging 44%, an insignificant rise in LDL cholesterol, and a significant increase in HDL cholesterol. In this group, responses to caloric restriction were similar to those of clofibrate therapy. 
Metabolism of VLDL-TG
Plasma radioactivity curves for VLDL-TG are shown during the three studies for one good responder in Figure 1 . Both clofibrate and caloric restriction reduced VLDL-TG and altered the shape of the turnover curve. However, the two regimens produced different changes in the curve shapes even though levels of VLDL-TG fell to about the same degree. Both regimens generally enhanced the downslope of the curve in the region between the peak and the tail (the period from 5 to 20 hours). On caloric restriction, the height of the tail was decreased relative to the peak, but during clofibrate therapy, there was little change in its height.
Kinetic data for all patients are summarized in Table 5. Compared to the mean total TG for the last 2 weeks of each period (Table 2) , average levels of VLDL-TG during the turnover study seemed unusually low during Period 3, although not in Periods 1 and 2. These relatively low concentrations of VLDL-TG in Period 3 may have been related to the fact that the turnover study was done at the end of the caloric restriction period when a maximum response should have been achieved. Furthermore, the relationship between the mean total TG of the last 2 weeks and the mean VLDL-TG level during the study varied somewhat among patients and between periods. This inconstancy was likely due to several factorsthe usual fluctuations in TG levels in hypertriglyceridemic patients, the maximal response at the end of each treatment period, and, in some patients, a mild rise in VLDL-TG levels during the equilibration portion of the turnover study. For comparison purposes, mean VLDL-TG concentrations of each period seem superior because they represent the average of 18 measurements at a time of maximal response.
The kinetic data for all patients are compared to those of 27 normolipidemic men studied by the same methods. The mean transport rate for VLDL-TG in the hypertriglyceridemic group averaged about twice normal before treatment, while their mean FCR was only slightly below normal. Treatment with clofibrate caused a decrease in VLDL-TG levels averaging 35%. The drug caused no reduction in mean transport in VLDL-TG, nor did it alter the fraction of the slow-synthesis pathway. It did, however, enhance the mean FCR of VLDL-TG by 33%. In contrast, caloric restriction, which overall caused a greater decrease in VLDL-TG concentrations than did clofibrate, significantly reduced the transport rate of VLDL-TG and increased the FCR of VLDL-TG.
Kinetic data for poor responders to clofibrate are shown in Table 6 . These patients did not have a significant decrease in VLDL-TG concentrations during drug therapy. Clofibrate likewise did not change transport rates of VLDL-TG; it did, however, cause a small but significant increase in FCR. In these poor responders, caloric restriction caused a significant reduction in transport rates of VLDL-TG and a small increase in FCR; the result was a significant decrease in VLDL-TG concentrations. The remaining patients were good responders to clofibrate ( Table 7) . They had significant reductions of VLDL-TG concentrations during drug therapy. Clofibrate also caused a small but significant decrease in mean transport rate of VLDL-TG; this reduction in transport rate, however, was substantially less than that caused by caloric restriction in these same patients. The fraction of VLDL-TG synthesis via the slow synthesis pathway was unchanged by clofibrate, but the slow path was distinctly curtailed by caloric restriction. The major change in kinetics induced by clofibrate was a 47% increase in FCR of VLDL-TG; a smaller increment in FCR (26%) also occurred during caloric restriction.
Discussion
This study was designed to compare the mechanisms whereby caloric restriction and clofibrate lower levels of plasma TG in patients with hypertri- glyceridemia. Caloric restriction is thought to mainly decrease the synthesis of VLDL-TG. The mechanisms by which clofibrate lowers plasma TG have been a matter of dispute; a reduced synthesis of VLDL-TG has been reported, 3 -7 but several studies claim enhanced clearance of VLDL-TG. 4 • 8 - 10 In this study we sought to explore these mechanisms by multicompartmental analysis to evaluate specific-activity curves of VLDL-TG. Previous evidence suggests that multicompartmental analysis provides a better interpretation of VLDL-TG kinetics than does single-exponential analysis of isotope decay curves. 1 If so, multicompartmental analysis could reveal the means by which various regimens lower plasma TG levels. Most patients in this report had mild-to-moderate hypertriglyceridemia due mainly to overproduction of VLDL-TG. The actions of caloric restriction and clofibrate therefore will be discussed as they affect patients with excessive input of VLDL-TG. Our conclusions might not be applicable to patients with other categories of hypertriglyceridemia such as those with defective clearance of TG-rich lipoproteins.
Effects of Caloric Restriction
For most of our patients, caloric restriction markedly reduced plasma TG concentrations, usually causing them to fall to the normal range. This decrease in levels was consistently associated with a lower production rate of VLDL-TG; in all cases, production rates during caloric restriction were within the normal range. This decrease in total production rates of VLDL-TG was accompanied by a decline in the fraction of VLDL-TG synthesis by the slow pathway.
Not only did restriction of calories lower production rates of VLDL-TG, but it also enhanced the FCR of this fraction. Theoretically, an increased FCR could have three causes. First, in the control period, lipolysis of plasma TG could have been saturated by overproduction of VLDL-TG, thereby causing a low FCR; with caloric restriction and decreased input of VLDL-TG, the FCR could have risen because of less saturation. This mechanism may have been operative in some patients. Second, caloric restriction might have enhanced the activity of lipoprotein lipase, but this response seems unlikely because of reports that this enzyme actually falls during caloric restriction. 23 -25 And third, if caloric restriction decreased the amount of TG in each newly secreted VLDL particle, hydrolysis of relatively small amounts of TG would rapidly convert VLDL to intermediate density lipoprotein (IDL); the result would be a higher FCR of VLDL-TG. This effect also was likely during caloric restriction.
What are the effects of caloric restriction on LDL metabolism? Since VLDL is a precursor of LDL, a reduced secretion of VLDL theoretically should lower plasma LDL. However, only two patients (Nos. 5 and 6) responded with a lower LDL cholesterol. The remainder had a rise in LDL, a response that has been noted previously. 17 How can this rise be explained? Patients with elevated plasma TG frequently have a high FCR of LDL, 26 which keeps LDL levels relatively low. Upon caloric restriction and normalization of VLDL-TG concentration, the FCR of LDL may return to normal causing a rise in LDL levels. As a general rule, however, LDL cholesterol levels in our patients did not increase strikingly during reduced caloric intake, although there were exceptions (Nos. 4 and 11).
Reduction of caloric intake often caused a rise in HDL cholesterol levels. The lipid components of HDL are thought to be derived in part from lipolytic products of VLDL; 27 however, since caloric restriction almost certainly did not stimulate lipolysis of VLDL, the rise in HDL cholesterol almost certainly cannot be explained by enhanced lipolysis. One factor contributing to a low HDL cholesterol in the hypertriglyceridemic state is the exchange of HDL cholesterol ester for TG of VLDL. 28 A lowering of plasma TG by either drug or diet should decrease the rate of exchange and hence raise HDL cholesterol.
Effects of Clofibrate
For the group as a whole, clofibrate significantly lowered the average concentrations of plasma TG and VLDL-TG. However, concentrations fell with clofibrate therapy less than during caloric restriction. The major and most consistent change caused by clofibrate was an enhanced fractional clearance of VLDL-TG. The mean production rate of VLDL-TG was unaffected by clofibrate compared to controls (Table 5 ). Still, the degree of reduction of VLDL-TG levels in response to clofibrate varied considerably. Several patients were poor responders to clofibrate, i.e., their VLDL-TG levels fell less than 20%. Although most of the poor responders had small increments in FCR of VLDL-TG, clofibrate generally did not change their production rates. The remainder were better responders to the drug, and they had decreases in production rates of VLDL-TG as well as increases in FCR. However, their production rates declined less on clofibrate than during caloric restriction, and on the average, secretion rates of VLDL-TG remained distinctly above normal despite clofibrate therapy.
Our results suggest that caloric restriction and clofibrate affect TG metabolism differently. The data support previous reports that caloric restriction mainly inhibits the synthesis of VLDL-TG. 229 Our results also substantiate claims that clofibrate promotes lipolysis of VLDL-TG, 48 -10 probably by enhancing the activity of lipoprotein lipase. 2730 - 32 Nonetheless, other investigators 3 -7 have reported that clofibrate decreases the production of VLDL-TG; although we could not show this action for the group as a whole nor in poor responders, the good responders to clofibrate did have a small but significant decrease in the production rates of VLDL-TG In line with the finding that clofibrate does not have a major effect on production of VLDL-TG, the drug also did not change the distribution of synthesis between fast and slow pathways. A lack of influence on the slow-synthesis pathway is revealed by the fact that clofibrate generally did not reduce the height of the tail of the specific-activity curve (Figure 1 ). This observation has methodological implications. Theoretically, the tail of the curve could be formed by either a slow-synthesis pathway or a slow-clearance pathway for VLDL-TG. If the tail of the curve is caused largely by a slow-clearance pathway, clofibrate, which enhances lipoprotein lipase, 27 -so- 32 should have reduced the height of the tail. The lack of change in tail height during clofibrate therapy supports the previous contention that the tail of the curve is due mainly to the slow-synthesis pathway. 1 Clofibrate caused a significant increase in the mean levels of LDL cholesterol. This effect might have been due in part to increased conversion of VLDL to LDL. Stimulation of lipoprotein lipase by clofibrate could promote transformation of VLDL to LDL at the expense of hepatic uptake of VLDL remnants. On the other hand, clofibrate could have slowed the fractional clearance of LDL. Hypertriglyceridemic patients usually have an abnormal composition of LDL 33 and frequently have a high FCR of LDL. 26 This high FCR of LDL may be secondary to the defect in LDL composition. Treatment with the clofibrate-analogue, bezafibrate, has been shown 33 to normalize the composition of LDL in hypertriglyceridemic patients, and assuming the same response to clofibrate, it could reduce FCR of LDL to normal. Both normalization of LDL composition and a fall in FCR of LDL would raise LDL cholesterol. Whether this rise in LDL is detrimental remains to be determined, but it is worrisome. Furthermore, for all patients, clofibrate raised LDL cholesterol more than did caloric restriction ( Table 2 ). In contrast, clofibrate increased HDL cholesterol less than did restriction of calories.
In summary, this investigation clearly reveals the limitations of clofibrate for treatment of hypertriglyceridemia. The drug mainly enhances lipolysis of VLDL-TG, while it has only a limited effect on the more important abnormality, overproduction of VLDL-TG. 34 Clofibrate can reduce VLDL-TG levels in patients with mild-to-moderate hypertriglyceridemia, but only at the expense of increasing LDL concentrations. Therefore, this drug would seem to have little place in the treatment of hypertriglyceridemia due to overproduction of VLDL. The current study also suggests that creation of a favorable energy balance through diet, or perhaps exercise, may be a valuable means to mitigate the excessive production of VLDL in many hypertriglyceridemic patients. Particularly for obese patients with elevated TG levels, weight reduction seems preferred to clofibrate therapy.
